title: Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.
abstract: There have been no paediatric randomised trials describing the effect of planned treatment interruptions (PTIs) of antiretroviral therapy (ART) on adherence, or evaluating acceptability of such a strategy. In PENTA 11, HIV-infected children were randomised to CD4-guided PTIs (n = 53) or continuous therapy (CT, n = 56). Carers, and children if appropriate, completed questionnaires on adherence to ART and acceptability of PTIs. There was no difference in reported adherence on ART between CT and PTI groups; non-adherence (reporting missed doses over the last 3 days or marking <100 % adherence since the last clinical visit on a visual analogue scale) was 18 % (20/111) and 14 % (12/83) on carer questionnaires in the CT and PTI groups respectively (odds ratios, OR (95 % CI) = 1.04 (0.20, 5.41), χ(2) (1) = 0.003, p = 0.96). Carers in Europe/USA reported non-adherence more often (31/121, 26 %) than in Thailand (1/73, 1 %; OR (95 % CI) = 54.65 (3.68, 810.55), χ(2) (1) = 8.45, p = 0.004). The majority of families indicated they were happy to have further PTIs (carer: 23/36, 64 %; children: 8/13, 62 %), however many reported more clinic visits during PTI were a problem (carer: 15/36, 42 %; children: 6/12, 50 %).
authors.affiliation: Medical Research Council Clinical Trials Unit, Aviation House, 125 Kingsway, London, WC2B 6NH, UK.
authors.forename: Linda
authors.initials: L
authors.lastname: Harrison
authors.forename: Jintanat
authors.initials: J
authors.lastname: Ananworanich
authors.forename: Djamel
authors.initials: D
authors.lastname: Hamadache
authors.forename: Alexandra
authors.initials: A
authors.lastname: Compagnucci
authors.forename: Martina
authors.initials: M
authors.lastname: Penazzato
authors.forename: Torsak
authors.initials: T
authors.lastname: Bunupuradah
authors.forename: Antonio
authors.initials: A
authors.lastname: Mazza
authors.forename: Jose Tomas
authors.initials: JT
authors.lastname: Ramos
authors.forename: Jacquie
authors.initials: J
authors.lastname: Flynn
authors.forename: Osvalda
authors.initials: O
authors.lastname: Rampon
authors.forename: Maria Jose
authors.initials: MJ
authors.lastname: Mellado Pena
authors.forename: Daniel
authors.initials: D
authors.lastname: Floret
authors.forename: Magdalena
authors.initials: M
authors.lastname: Marczynska
authors.forename: Ana
authors.initials: A
authors.lastname: Puga
authors.forename: Silvia
authors.initials: S
authors.lastname: Forcat
authors.forename: Yoann
authors.initials: Y
authors.lastname: Riault
authors.forename: Marc
authors.initials: M
authors.lastname: Lallemant
authors.forename: Hannah
authors.initials: H
authors.lastname: Castro
authors.forename: Diana M
authors.initials: DM
authors.lastname: Gibb
authors.forename: Carlo
authors.initials: C
authors.lastname: Giaquinto
mesh_terms: D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D017028:Caregivers / Q000523:psychology; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D006801:Humans; D008297:Male; D055118:Medication Adherence; D010342:Patient Acceptance of Health Care; D011795:Surveys and Questionnaires; D013785:Thailand; D014481:United States; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents